Search

Protagonist Therapeutics Inc

Gesloten

SectorGezondheidszorg

150.49 -2.69

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

149.51

Max

157.19

Belangrijke statistieken

By Trading Economics

Inkomsten

159M

163M

Verkoop

157M

213M

K/W

Sectorgemiddelde

154

57.371

EPS

2.29

Winstmarge

76.285

Werknemers

141

EBITDA

162M

165M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+5.84% upside

Dividenden

By Acuity

Volgende Winsten

4 nov 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

1.8B

10B

Vorige openingsprijs

153.18

Vorige sluitingsprijs

150.49

Nieuwssentiment

By Acuity

50%

50%

150 / 340 Rangschikking in Healthcare

Protagonist Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

24 aug 2026, 20:06 UTC

Protagonist Therapeutics shares are higher today, recovering from an earlier dip. The broader market also shows slight gains since Friday's close.

21 aug 2026, 20:06 UTC

Protagonist Therapeutics Inc is rising during Friday's session, showing steady gains since Thursday amid a broader market boost from Bitcoin's surge.

20 aug 2026, 19:31 UTC

Correlated Moves

Protagonist Therapeutics Inc shares are lower today amid a decline in the Biotechnology sector, with unusually high trading volume noted during the session.

19 aug 2026, 19:46 UTC

Protagonist Therapeutics Inc shares are lower today, retracing from earlier highs. The price remains above its 20-day moving average amid no specific news.

17 aug 2026, 19:46 UTC

Social Media
News

BMO Capital raised Protagonist Therapeutics' price target to $178, maintaining an Outperform rating, as shares trade higher amid positive pipeline developments.

14 aug 2026, 22:36 UTC

Protagonist Therapeutics Inc shares are higher in after-market trading, remaining above their 20-day moving average and near the upper end of their one-month range.

13 aug 2026, 20:06 UTC

Correlated Moves
News
Social Media

Protagonist Therapeutics shares are lower amid insider selling concerns following CEO Dinesh V. Patel's recent stock transactions. The decline reflects broader sector trends.

12 aug 2026, 23:31 UTC

Social Media

Protagonist Therapeutics Inc gains after-market, reaching a high above Wednesday's close. Investor interest grows amid social media discussions on increasing positions.

11 aug 2026, 23:01 UTC

Protagonist Therapeutics Inc shares are higher in after-market hours, though no specific news explains the movement amid earlier volatility and fluctuations.

10 aug 2026, 23:46 UTC

Protagonist Therapeutics Inc shares are higher in after-market hours, with notable strength above the 20-day moving average and near the upper end of its one-month range.

6 aug 2026, 19:52 UTC

Social Media
News

Protagonist Therapeutics shares rise following multiple price target upgrades, including Citi's increase to $175, amid positive sentiment on drug approvals and pharmacokinetic data.

5 aug 2026, 22:02 UTC

News

Protagonist Therapeutics reports Q2 net income of $162.8 million, up from a loss last year. Shares are higher in after-market trading following the results.

4 aug 2026, 21:03 UTC

Protagonist Therapeutics Inc shares are higher in after-market trading, supported by their position above the 20-day moving average. No specific news was identified.

3 aug 2026, 19:36 UTC

Protagonist Therapeutics Inc shares are lower today, continuing a decline since Friday. The stock is near the lower end of its one-month range.

31 jul 2026, 19:36 UTC

Correlated Moves

Protagonist Therapeutics Inc is lower today amid broader weakness in the Biotechnology sector. Earlier in the session, shares pulled back from a high.

30 jul 2026, 21:02 UTC

Protagonist Therapeutics Inc shares are higher in after-market trading, amid notable volatility and significant price swings since Thursday's close.

29 jul 2026, 19:43 UTC

Macro Event

Protagonist Therapeutics Inc shares are lower amid market volatility following the Federal Reserve's decision to maintain interest rates, reflecting broader uncertainty.

28 jul 2026, 21:01 UTC

Protagonist Therapeutics Inc shares are higher in after-market trading, maintaining a notable gain since Tuesday's close, despite no specific news identified.

27 jul 2026, 20:02 UTC

Social Media

Protagonist Therapeutics shares are lower despite Jefferies raising its price target to $171 and Cowen increasing its peak royalty revenue forecast to $1.4 billion.

22 jul 2026, 19:42 UTC

News

Protagonist Therapeutics Inc is trading lower today, continuing a decline since Tuesday amid rising crude oil prices and market tensions related to Iran.

21 jul 2026, 19:06 UTC

Protagonist Therapeutics Inc shares are higher today, continuing an upward trend since Monday's close, supported by gains in the semiconductor sector.

20 jul 2026, 19:41 UTC

News
Social Media

Protagonist Therapeutics shares are lower as analysts raise price targets and revenue forecasts ahead of Q2 earnings, despite a noted 0% probability of success for PN-881.

Peer Vergelijking

Prijswijziging

Protagonist Therapeutics Inc Prognose

Koersdoel

By TipRanks

5.84% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 163.75 USD  5.84%

Hoogste 186 USD

Laagste 121 USD

Gebaseerd op 12 Wall Street-analisten die 12-maands prijsdoelen bieden voor Protagonist Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

12 ratings

12

Buy

0

Hold

0

Sell

Sentiment

By Acuity

150 / 340 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Protagonist Therapeutics Inc

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
help-icon Live chat